COVID-19: coagulopathy, risk of thrombosis, and the rationale for anticoagulation

  • The novel coronavirus infection (COVID-19) is caused by the new coronavirus SARS-CoV-2 and is characterized by an exaggerated inflammatory response that can lead to severe manifestations such as adult respiratory syndrome, sepsis, coagulopathy, and death in a proportion of patients. Among other factors and direct viral effects, the increase in the vasoconstrictor angiotensin II, the decrease in the vasodilator angiotensin, and the sepsis-induced release of cytokines can trigger a coagulopathy in COVID-19. A coagulopathy has been reported in up to 50% of patients with severe COVID-19 manifestations. An increase in d-dimer is the most significant change in coagulation parameters in severe COVID-19 patients, and progressively increasing values can be used as a prognostic parameter indicating a worse outcome. Limited data suggest a high incidence of deep vein thrombosis and pulmonary embolism in up to 40% of patients, despite the use of a standard dose of low-molecular-weight heparin (LMWH) in most cases. In addition, pulmonary microvascular thrombosis has been reported and may play a role in progressive lung failure. Prophylactic LMWH has been recommended by the International Society on Thrombosis and Haemostasis (ISTH) and the American Society of Hematology (ASH), but the best effective dosage is uncertain. Adapted to the individual risk of thrombosis and the d-dimer value, higher doses can be considered, especially since bleeding events in COVID-19 are rare. Besides the anticoagulant effect of LMWH, nonanticoagulant properties such as the reduction in interleukin 6 release have been shown to improve the complex picture of coagulopathy in patients with COVID-19.

Download full text files

Export metadata

Additional Services

Share in Twitter Search Google Scholar
Metadaten
Author:Wolfgang MiesbachORCiDGND, Michael Makris
URN:urn:nbn:de:hebis:30:3-569058
DOI:https://doi.org/10.1177/1076029620938149
ISSN:1938-2723
ISSN:1076-0296
Pubmed Id:https://pubmed.ncbi.nlm.nih.gov/32677459
Parent Title (English):Clinical and applied thrombosis/hemostasis
Publisher:Sage
Place of publication:Thousand Oaks, Calif.
Document Type:Article
Language:English
Date of Publication (online):2020/07/17
Date of first Publication:2020/07/17
Publishing Institution:Universit├Ątsbibliothek Johann Christian Senckenberg
Release Date:2020/11/18
Tag:COVID-19; anticoagulation; thrombosis
Volume:26
Page Number:7
HeBIS-PPN:476902622
Institutes:Medizin / Medizin
Dewey Decimal Classification:6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit
Sammlungen:Universit├Ątspublikationen
Licence (German):License LogoCreative Commons - Namensnennung 4.0